Torrent Pharma to Acquire Three Diabetes Brands, Boosting SGLT-2 Market Presence

Torrent Pharma to Acquire Three Diabetes Brands, Boosting SGLT-2 Market Presence

Torrent Pharmaceuticals has signed a deal with Boehringer Ingelheim to acquire diabetes brands Cospiaq, Cospiaq Met, and Xilingio, enhancing its portfolio in the growing SGLT-2 inhibitor market worth ₹3,235 crore. These brands, featuring empagliflozin-based therapies, have been co-marketed by Torrent since 2022. The ₹19,912 crore Indian diabetes medication market, growing at 7.7% annually, reflects India's rising diabetes cases, projected to reach 125 million by 2045. The deal, set for completion by March 2025, strengthens Torrent’s focus on diabetes care, despite its stock dipping 0.31% to ₹3,352.65 on the NSE.

Trending News